October 19, 2010
Iron deficiency affects approximately 45 percent of all
inflammatory bowel disease (IBD) patients, and 30 percent suffer
from anemia1. These conditions negatively impact the
quality of life of IBD patients, so gastroenterologists are
increasingly focused on the importance of iron replacement therapy
in the care management of this patient group.
At the 2010 UEGW congress,
Pharmacosmos is pleased to host a special satellite symposium
focused on the best practice management of iron deficiency anemia
in patients suffering from IBD. Entitled "State-of-the-Iron: How do
we diagnose and efficiently treat iron deficiency anemia in
inflammatory bowel disease?", the symposium will be held on Monday
25 October from 18:00-19:30.
The event gathers leading international experts in the field of
gastroenterology to discuss how physicians can improve the
treatment outcome of IBD patients suffering from iron deficiency.
The panel of experts includes Dr. Michael Staun (Denmark), Dr.
Arthur Kaser (Austria), Dr. Manual Munoz (Spain) and Dr. Sunil
Bhandari (United Kingdom). Chaired by Dr. Walter Reinisch
(Austria), the sessions will discuss best practices in the early
detection and efficacious treatment of iron deficiency in IBD
Pharmacosmos wishes the panel and the congress participants an
enjoyable symposium full of fruitful discussions and shared
To download the symposium invitation and sign up for
Pharmacosmos updates to receive the key symposium slides, please
Andreas Sidelmann Christensen
Corporate Communications Manager, M.Sc.
T: +45 59 48 60 26
1) Muñoz M. et al. World J Gastroenterol
© 2010 Pharmacosmos A/S.
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 50 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug